Needham & Co. upgraded Medtronic to Buy from Hold, citing a wave of new product launches across large markets that should lift revenue growth and improve execution over the next several years. The brokerage expects the company's latest devices and systems to accelerate organic growth, with new products alone potentially adding more than 1% to overall revenue expansion.

Based on its $36 billion fiscal 2026 revenue estimate, Needham said Medtronic would need about $360 million in incremental annual sales to reach that threshold, which it believes is achievable by the end of 2026. The firm highlighted several launches as key drivers, including Medtronic's pulsed field ablation products gaining traction in the roughly $13 billion electrophysiology market and the Symplicity Spyral renal denervation system after Medicare coverage was finalized, targeting a U.S. market estimated at about $6 billion.

FDA approval for urological surgery using the Hugo robotic system opens access to the roughly $7 billion U.S. soft-tissue robotics market. Other recent launches, including the AltaViva tibial nerve stimulation device, are expected to contribute to growth across multiple business lines. Needham said Elliott Management's involvement and the addition of new board members should strengthen execution, support organic growth and improve profitability. The company has formed new board committees focused on growth strategy and operating performance and is planning an investor day in 2026.